MOODY’S-ESG-SOLUTIONS
Moody’s announced today that it has appointed Emilie Mazzacurati as Global Head of Moody’s Climate Solutions. In this newly-established role, Ms. Mazzacurati will oversee the climate solutions suite within Moody’s ESG Solutions Group, a new business unit formed earlier this year to serve the growing global demand for ESG and climate analytics. Ms. Mazzacurati will report to Andrea Blackman, Global Head of Moody’s ESG Solutions.
“As global awareness and recognition of the financial risks posed by climate change increase, Moody’s is committed to meeting market needs for forward-looking, science-driven climate analytics that help advance a resilient financial system, responsible capitalism, and the greening of the economy,” said Ms. Blackman. “Emilie’s extensive climate expertise will be vital to our continued development of climate solutions and to ensuring that Moody’s is a leading voice in this important area.”
As part of its climate solutions suite, Moody’s ESG Solutions provides risk measurement and evaluation tools to understand, quantify and manage climate risks for physical and transition risk, informing due diligence and risk disclosure in line with the recommendations from the Taskforce on Climate-related Financial Disclosures (TCFD).
Climate risk analytics from Moody’s ESG Solutions are also integrated into Moody’s Analytics risk management tools, translating climate risk exposure into financial impact and credit risk metrics for banks, insurers, and investors. Similarly, the group’s climate data and insights are increasingly being leveraged in Moody’s Investors Service credit analysis. By offering data and analytics across asset classes, including listed and unlisted companies, real estate, infrastructure, sovereigns and municipalities, Moody’s ESG Solutions supports the integration of climate-related risks into financial decision-making and risk management.
Moody’s ESG Solutions climate offerings build on the award-winning physical climate risk analytics from Four Twenty Seven, a leading provider of climate risk data and market intelligence, founded by Ms. Mazzacurati in 2012. Moody’s acquired a majority stake in Four Twenty Seven in 2019 and recently took full ownership. Moody’s climate solutions suite also leverages data from V.E, a Moody’s affiliate with expertise in transition risk, ESG, and corporate disclosures.
ABOUT MOODY’S ESG SOLUTIONS
Moody’s ESG Solutions Group is a business unit of Moody’s Corporation serving the growing global demand for ESG and climate insights. The group leverages Moody’s data and expertise across ESG, climate risk, and sustainable finance, and aligns with Moody's Investors Service (MIS) and Moody's Analytics (MA) to deliver a comprehensive, integrated suite of ESG and climate risk solutions including ESG scores, analytics, Sustainability Ratings and Sustainable Finance Reviewer/certifier services.
For more information visit Moody’s ESG & Climate Risk hub at www.moodys.com/esg
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005565/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy7.11.2025 17:00:00 CET | Press release
− Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 Months After Last Dose1− Rapid Reductions in Proteinuria and Serum Gd-IgA1 Levels Were Sustained Through Week 961− No Serious Adverse Events or Opportunistic Infections Were Observed Through Week 961− Takeda Initiated Pivotal Phase 3 Clinical Trials Evaluating Mezagitamab in Primary IgA Nephropathy and Immune Thrombocytopenia with Patient Enrollment Ongoing Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The results were presented at the American Society o
Oremus Corporate Services Expands into Europe with Launch in Finland7.11.2025 16:23:00 CET | Press release
CEO, Lalit Ananth Chawla, to Attend Slush 2025 in Helsinki Oremus Corporate Services Private Limited, a multinational Finance and Accounting Advisory firm having its offices in the USA, India and the UK, has announced the extension of its services to Finland, marking the company’s foray into the European market. With over two decades of expertise in accounting, payroll, tax compliance, and advisory services, Oremus has earned trust as a technology-driven finance partner serving clients across geographies. Oremus is an ISAE 3402, ISO 27001, GDPR & DPDP Compliant Company, adhering to International Quality and Security Standards. “Finland isn’t just a new market for us — it’s the gateway to meaningful, growth-driven partnerships across Europe”. said Lalit Ananth Chawla, CEO of Oremus. Having established a strong reputation for delivering reliable Accounting and Advisory solutions to scale-ups and growing businesses, we seek to collaborate with like-minded firms and investors to build a tr
Experian Named a Leader in IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment7.11.2025 15:00:00 CET | Press release
Advanced fraud prevention, multi-layered verification and innovative data-driven security solutions are core to Experian’s Ascend Platform™ Experian today announced it has been named a leader in the IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment (doc # US52985325, September 2025). The report evaluates vendors on the depth and breadth of their identity verification capabilities and on how effectively they align with current and future customer needs. The IDC MarketScape methodology for this assessment involved two key measures of success: capabilities that reflect Experian’s current menu of services and how well aligned they are to its customer needs as well as strategies that indicate how well Experian’s future strategy aligns with what customers will require in three to five years. “This assessment offers a 360-degree view of our identity-verification solutions, and we’re very proud to be recognized as a leader,” said Keith Little, Presid
Rachelle Alexis Lim is appointed CEO of MultiSafepay as the Company Aims to Better Serve European SMEs with Innovative Solutions7.11.2025 14:12:00 CET | Press release
Digital payments veteran Rachelle Alexis Lim now spearheads MultiSafepay’s operational strategy as it brings its innovative omnichannel payment platform to businesses of all sizes across Europe, driving inclusive growth for SMEs. Founder, Olaf Geurs, who has led MultiSafepay for nearly three decades will remain Chief Technology Officer and hold his position on the board of directors. In this role he will remain instrumental to driving innovation. Since the start of its strategic partnership with global payment and digitisation provider Antom, MultiSafepay's transaction volume has nearly doubled, and its merchant base has increased by over a quarter. MultiSafepay, a leading European payment service provider, today announces that Rachelle Alexis Lim has been appointed as the new Chief Executive Officer (CEO) of MultiSafepay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107657130/en/ Rachelle Alexis Lim is appointed CEO of
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie7.11.2025 13:30:00 CET | Press release
Net proceeds will be applied to debt reduction, advancing Organon’s ongoing deleveraging effortsPositions Organon for future investment in growth opportunities with a focus on women’s health biopharma and other strategic prioritiesLaborie’s capabilities in medical technology will facilitate broader access to JADA for more mothers Organon (NYSE: OGN), (“Organon” or “the Company”) a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement with Laborie Medical Technologies Corp. (“Laborie”), a leading diagnostic and therapeutic medical technology company, for them to acquire the JADA System. The transaction, valued at up to $465 million, is comprised of $440 million to be paid at closing, subject to certain closing adjustments, and a potential payment of up to $25 million subject to the achievement of certain 2026 revenue targets. Approximately 100 employees are expected to transf
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom